Burning rock's precision oncology diagnostics product supports advancement in late-stage breast cancer treatment, with results published in the new england journal of medicine

Guangzhou, china, june 08, 2023 (globe newswire) -- burning rock biotech limited (nasdaq: bnr and lse: bnr, the “company” or “burning rock”) is pleased to announce that our flagship comprehensive genomic profiling (cgp) product, oncoscreentm plus, was featured in a phase 3 multi-regional clinical trial (mrct), along with foundationonecdx, in support of advancement in breast cancer treatment.
BNR Ratings Summary
BNR Quant Ranking